Volltext-Downloads (blau) und Frontdoor-Views (grau)
  • search hit 7 of 204
Back to Result List

Bitte verwenden Sie diesen Link, wenn Sie dieses Dokument zitieren oder verlinken wollen: https://nbn-resolving.org/urn:nbn:de:gbv:9-opus-31042

Efficacy of Trabectedin in Patients with Advanced or Metastatic Alveolar Soft-Part Sarcoma

  • Background: Alveolar soft-part sarcoma (ASPS) is a rare sarcoma often occurring in young patients that is characterized by the unbalanced translocation der(17)t(X;17) (p11;q25). Although itusuallyshowsan indolent clinical course, the prognosis is usually poor in advanced disease. Since standard chemotherapy regimens used in soft-tissue sarcomas lack efficacy in ASPS, new therapeutic options are needed. We investigated the efficacy of trabectedin, which has demonstrated activity in a variety of cancer types including some of the most prevalent translocation-related sarcomas. Patients and Methods: 7 patients with metastatic or advanced ASPS treated with trabectedin in the Sarcoma Center Berlin-Brandenburg and the University Hospital of Greifswald were analyzed for median progression-free survival (mPFS), overall survival (OS), and therapy-related toxicity. Results: In 6 patients with documented disease progression, disease stabilization was reached with trabectedin; only 1 patient experienced progressive disease. The mPFS and OS were 7 months and 21 months, respectively, since the start of trabectedin treatment. Overall, no severe Common Toxicity Criteria (CTC) grade 3 or 4 toxicity was observed. Conclusions: The poor prognosis of patients with ASPS has so far been due to the unavailability of effective systemic treatments. Trabectedin can be considered the only currently registered drug with clinical activity in this disease.

Download full text files

Export metadata

Additional Services

Search Google Scholar

Statistics

frontdoor_oas
Metadaten
Author: Daniel Pink, Janina Bertz-Lepel, Christoph Busemann, Ulrich Bitz, Peter Reichardt
URN:urn:nbn:de:gbv:9-opus-31042
URL:http://www.karger.com/onk
DOI:https://doi.org/10.1159/000338342
ISSN:2296-5270
ISSN:2296-5262
Pubmed Id:https://pubmed.ncbi.nlm.nih.gov/22868503
Parent Title (English):Oncology Research and Treatment
Publisher:S. Karger AG
Place of publication:Basel, Switzerland
Document Type:Article
Language:English
Date of first Publication:2012/04/23
Release Date:2020/09/29
Tag:ASPS; Trabectedin
GND Keyword:-
Volume:35
Issue:5
First Page:249
Last Page:252
Faculties:Universitätsmedizin
Licence (German):License LogoUrheberrechtlich geschützt